Advisory Committees

Drug Safety and Risk Management Advisory Committee Charter

Authority

The Drug Safety and Risk Management Advisory Committee was established under 15 U.S.C. 1451 et seq.; 21 U.S.C. 321, 341, 342, 343, 343-1, 344, 345, 346, 348, 349, 350, 350a, 351, 352, 353(f), 355, 360b, 360c-j, 371, 375,376,378, 379e, 381,393, 394, 88l(b); 42 U.S.C. 217a, 241, 242, 242a, 262, 264; 21 CFR Part 14, 330.IO(a); Pub. L. 92-463 (5 U.S.C. App.), the Federal Advisory Committee Act, which sets forth standards for the formation and use of advisory committees.

Objectives and Scope of Activities

The Drug Safety and Risk Management Advisory Committee advises the Commissioner or designee in discharging responsibilities as they relate to helping to ensure safe and effective drugs for human use and, as required, any other product for which the Food and Drug Administration has regulatory responsibility.

Description of Duties

The Committee reviews and evaluates information on risk management, risk communication, and quantitative evaluation of spontaneous reports for drugs for human use and for any other product for which the Food and Drug Administration has regulatory responsibility. The Committee also advises the Commissioner of Food and Drugs regarding the scientific and medical evaluation of all information gathered by the Department of Health and Human Services and the Department of Justice with regard to safety, efficacy, and abuse potential of drugs or other substances, and recommends actions to be taken by the Department of Health and Human Services with regard to the marketing, investigation, and control of such drugs or other substances.

Agency or Official to Whom the Committee Reports

The Committee provides advice to the Commissioner of Food and Drugs.

Support

Management and support services shall be provided by the Center for Drug Evaluation and Research.

Estimated Annual Operating Costs and Staff Years

The estimated annual cost for operating the Committee, including compensation and travel expenses for members but excluding staff support, is $145,650. The estimated person years of staff support required is 1.10 at an estimated annual cost of $120,094.

Designated Federal Officer

FDA will select a full-time orpermanent part-time Federal employee to serve as the Designated Federal Officer (DFO) to attend each Committee meeting and ensure that all procedures are within applicable statutory, regulatory, and HHS General Administration Manual directives. The DFO will approve and prepare all meeting agendas, call all ofthe Committee and subcommittee meetings, adjoum any meeting when the DFO determines adjournment to be in the public interest and chair meetings when directed to do so by the official to whom the Committee reports. The DFO shall be present at all meetings ofthe full committee and subcommittees.

Estimated Number and Frequency of Meetings

Meetings shall be held approximately 4 times a year. Meetings shall be open to the public except as determined otherwise by the Commissioner or designee in accordance with the Government in the Sunshine Act (5 U.S.C. 552b(c)) and the Federal Advisory Committee Act. Notice of all meetings shall be given to the public.

Duration

Continuing

Termination

Unless renewed by appropriate action the Drug Safety and Risk Management Advisory Committee will terminate two years from the date the charter is filed.

Membership and Designation

The Committee shall consist of a core of 11 voting members including the Chair. Members and the Chair are selected by the Commissioner or designee from among authorities knowledgeable in the fields of risk communication, risk management, drug safety, medical, behavioral, and biological sciences as they apply to risk management, and drug abuse. Members will be invited to serve for overlapping terms of up to four years. Almost all non-Federal members of this committee serve as Special Government Employees. The core of voting members may include one technically qualified member, selected by the Commissioner or designee, who is identified with consumer interests and is recommended by either a consortium of consumer-oriented organizations or other interested persons. In addition to the voting members, the Committee may include one non-voting member who is identified with industry interests.

The Commissioner ordesignee shall have the authority to select members ofother scientific and technical FDA advisory committees (normally not to exceed 10 members) to serve temporarily as voting members and to designate consultants to serve temporarily as voting members when: (1) expertise is required that is not available among current voting standing members of the Committee (when additional voting members are added to the Committee to provide needed expertise, a quorum will be based on the combined total of regular and added members), or (2) to comprise a quorum when, because of unforeseen circumstances, a quorum is or will be lacking. Because of the size ofthe Committee and the variety in the types of issues that it will consider, FDA may, inconnection with a particular committee meeting, specify a quorum that is less than a majority of the current voting members. The Agency's regulations (21 CFR §14.22(d)) authorize a committee charter to specify quorum requirements.

If functioning as a medical device panel, a non-voting representative of consumer interests and a non-voting representative of industry interests will beincluded in addition to the voting members.

Subcommittee

Temporary subcommittees consisting of two or more Committee members may be established by the Commissioner or designee as needed to address specific issues within their respective areas of expertise.

Subcommittees make preliminary recommendations regarding specific issues for subsequent action by the full Committee. The Department Committee Management Officer shall be notified upon establishment of each subcommittee, and shall be provided information on its name, membership, function, and estimated frequency of meetings.

Recordkeeping

The records of the Committee, established subcommittees, or other subgroups of the committee, shall be handled in accordance with General Records Schedule 26, Item 2 or other approved agency records disposition schedule.

Filing Date

May 31, 2014

Approved:

Date
5/14/2014

Jill Hartzler Warner, J.D.
Associate Commissioner for Special
Medical Programs (Acting), FDA

NOTICE OF RENEWAL OF THE DRUG SAFETY AND RISK MANAGEMENT ADVISORY COMMITTEE

I determine that renewal of the Drug Safety and Risk Management Advisory Committee beyond May 31,2014, is in the public interest in connection with the performance of duties imposed on the Food and Drug Administration by law, and that such duties can best be performed through the advice and counsel of such agroup. Therefore, the Committee is continued until May 31, 2016.

I deem that it is not feasible forthe Food and Drug Administration or any of its existing committees to perform these duties, and that a satisfactory plan for appropriate balance of the Committee membership exists.

Date
5/14/2014

Jill Hartzler Warner, J.D.
Associate Commissioner for Special
Medical Programs (Acting), FDA

Page Last Updated: 09/16/2014
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.